1. Medtech Insight
  2. >>Geography

China’s Mass COVID Testing: Players And Profits Behind The Policy

New Billionaires Created

 
• By Brian Yang

Even at $2.40 per test, tens of millions of tests provided add up quickly to deplete China’s medical insurance pool. Now the government wants localities to step and pay.

BEIJINGERS LINED UP FOR COVID PCR TESTING IN APRIL 2022
BEIJINGERS LINING UP FOR COVID PCR TESTING IN APRIL 2022 • Source: Brian Yang/MTI

Since COVID infections flared up in Beijing a month ago, non-stop testing has been conducted daily across hundreds of sites scattered around the sprawling city.

All residents of communities with even one confirmed infection are required to go through the PCR testing daily. One resident of Beijing’s affluent neighborhoods noted that he had to get...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Asia

More from Geography

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.